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Background: Adequate biomarkers for the dietary supply of fatty acids (FA) are FA of adipose tissue and blood
fractions. In human studies, invasive sample collection is unpleasant for subjects. In contrast, cheek cell sampling
can be considered as a non-invasive alternative to investigate FA status.
The aim of this study was to analyze whether cheek cell FA composition reflect the supplementation of alpha-linolenic
acid (ALA) using a linseed oil mixture compared to olive oil supplementation. Additionally, it was investigated if cheek
cell FA composition correlates with the FA composition of plasma, red blood cells (RBC) and peripheral blood
mononuclear cells (PBMC) before and during both interventions.
Methods: During a 10-week randomized, controlled, double-blind human intervention study, 38 subjects provided
cheek cell and blood samples. After a two-week run-in period, the test group (n = 23) received 17 g/d of an ALA-rich
linseed oil mixture, while the control group (n = 15) received 17 g/d of an omega-3 (n-3) polyunsaturated FA
(PUFA)-free olive oil. Cheek cells and blood were collected on days 0, 7 and 56 of the 8-week intervention period.
Results: Compared to olive oil, the linseed oil intervention increased ALA and also the endogenously converted
long-chain n-3 metabolites eicosatetraenoic-, eicosapentaenoic- and docosapentaenoic acid in cheek cells (P ≤ 0.05).
Docosahexaenoic acid remained unchanged. Reflecting the treatment, the n-6/n-3 ratio decreased in the test group. In
general, cheek cell FA reflected the changes of FA in blood fractions. Independent of treatment, significant correlations
(P≤ 0.05) of n-6 PUFA and n-3 PUFA between cheek cells and plasma, RBC and PBMC were found, except for linoleic
acid and ALA.
Conclusions: The changes in FA composition of cheek cells confirmed that ALA from linseed oil increased
endogenously derived n-3 PUFA in cheek cell lipids. These changes in cheek cells and their correlation to the
respective FA in blood fractions indicate the cheek cell FA profile as an adequate non-invasive biomarker for short-term
n-3 PUFA intake and metabolism. Therefore, cheek cell FA can be used in human intervention studies or large-scale
epidemiological studies, especially for assessment of the n-3 PUFA status.
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Based on ongoing discussions about the effect of dietary
fat quality on chronic diseases including cardiovascular
diseases (CVD) [1], it is of increasing interest to qualita-
tively and quantitatively assess dietary intake of fatty acids
(FA). A special focus is on omega-3 (n-3) polyunsaturated
FA (PUFA) intake and their enrichment in the body.
There have been numerous reports on the physiologically
beneficial effects of n-3 PUFA, including a reduction of
CVD risk [1,2], anti-inflammatory effects [1,3] and asso-
ciations with mental health [4,5]. A desire exists to find an
adequate biomarker that can reflect the FA intake and FA
status in humans [6]. However, a satisfying gold standard
biomarker that adequately reflects FA intake and status
does not exist. Food frequency questionnaires as used in
large-scale population studies only allow speculations on
the dietary FA intake but not on the enrichment of FA in
the body pool. The n-3 index which can be determined
from red blood cells (RBC) is considered a biomarker, or
even a risk factor, for CVD [7]. However, the collection
procedure for measurement of FA in RBC or other bio-
markers of choice as FA of whole blood, plasma, blood
cells, and adipose tissue [8,9], is invasive and an additional
burden to subjects in human intervention studies.
To overcome such problems, the use of cheek cells as
an alternative material reflecting dietary FA compo-
sition has been proposed [10,11]. In that context,
McMurchie et al. were the first to use cheek cell FA for
the assessment of the FA composition in humans [12].
Cheek cells have a rapid and constant turnover and
show a fast regeneration time of approximately 5 days
[13]. Therefore, cheek cell FA are thought to reflect
short-term changes in the diet [11]. Cheek cells can be
obtained by a mouthwash or by scraping the inside of a
cheek, e.g. with a brush [11,12]. Along with its non-
invasive nature, utilizing cheek cells is cost effective and
can be applied in a non-clinical environment without
medicinal personal on a large scale [14]. This method is
especially advantageous when used with infants or chil-
dren, as they are often afraid of blood sampling. Moreover,
this procedure might also be an improvement for the eld-
erly, as blood removal can be difficult due to inaccessible
veins. However, despite its convenience and applicability,
the use of cheek cell FA as a biomarker for FA intake and
n-3 PUFA status has rarely been used in human interven-
tion studies and is not yet fully established. One reason
could be the small sample amount of cheek cells obtained,
which requires precise sampling procedures for sufficient
cell amounts [11,14].
To validate the method’s significance, the aim of the
present study was to detect the FA composition of cheek
cells with focus on n-3 PUFA without intervention and
during supplementation with either alpha-linolenic acid
(ALA)-rich linseed oil mixture or with n-3 PUFA-freeolive oil. Additionally, it was of interest if the cheek
cell FA composition correlates to the FA composition of
plasma, RBC and peripheral blood mononuclear cells
(PBMC).
Study design and methods
The double-blind, parallel arm, randomized, controlled
study was approved by the ethics committee of the Friedrich
Schiller University of Jena (No. 2270-04/08) and is regis-
tered in Clinical Trials (NCT01317290). The implemen-
tation of the study and all sample analyses were carried
out at the Department of Nutritional Physiology of the
Friedrich Schiller University Jena, Germany.
Subjects
The present cheek cell study was part of a main study. In
the main project a total of 77 subjects were recruited for
the entire study from the general population by advertise-
ment. Participants were randomly allocated to a test group
with linseed oil intervention and a control group with
olive oil intervention using computer-generated random
numbers according to age, gender, and BMI. Exclusion
criteria were pregnancy, lactation, lactose intolerance,
chronic diseases, and medication influencing fat metabo-
lism or inflammation.
From the total study population 43 healthy subjects
with BMI < 25 (23 subjects of the test group and 20 sub-
jects of the control group) were willing to donate cheek
cell samples in addition to blood samples and therefore
built the cheek cell subgroup. Unfortunately, baseline
values of 5 control subjects were not available, thus the
cheek cell subgroup was created by 23 participants (13
males, 10 females) receiving the test oil and only 15 par-
ticipants (6 males, 9 females) receiving the control oil
(Table 1). Before enrollment into the study, all subjects
were required to sign a declaration of consent. A base-
line questionnaire about health, lifestyle and nutritional
habits was completed by each participant. At the end of
the study, an anonymous compliance protocol of the
study regime was completed by the subjects. In addition,
compliance was measured by counting used oil packets.
Study design and supplements
The duration of the study was 10 weeks, separated into
two periods: a two-week run-in period and an eight-
week intervention period. During the entire study, sub-
jects were not allowed to consume fish, fish-oil, n-3
PUFA-rich oils and linseeds. A three-day standardized
diet was provided to the subjects in the last days of each
study period. No other food consumption was intended
during the standardized diet [15]. Blood and cheek cell
sampling was conducted at the end of the run-in period
(day 0), after one week of intervention (day 7) and at the
end of the intervention (day 56).
Table 1 Baseline characteristics of study participants
Test group Control group
Linseed oil mix (n = 23) Olive oil (n = 15)
Mean ± SD Median Mean ± SD Median P
Age [years] 28.1 ± 11.1 25.0 38.1 ± 17.9 25.0 0.1801
Body weight [kg] 66.2 ± 9.9 66.3 66.4 ± 11.8 70.9 0.9612
Body mass index [kg/m2] 22.2 ± 2.2 22.0 22.6 ± 2.8 22.2 0.5992
Waist circumference [cm] 81.2 ± 5.0 81.0 82.3 ± 9.7 83.0 0.6922
Blood pressure systolic [mmHg] 134 ± 17.3 133.0 134 ± 14.1 134.0 0.8692
Blood pressure diastolic [mmHg] 82.9 ± 6.7 82.0 85.3 ± 7.1 85.0 0.2402
Differences between the test group and control group: 1P value according to Mann Whitney U test, 2P value according to student t test.
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free run-in oil mixture with a FA composition of an ave-
rage Western diet was given as a supplement (Table 2).
The run-in oil was provided as a spread and consisted of
different fats and oils (coconut fat, palm oil, palm kernel
fat, olive oil, sunflower oil, and chocolate cream). The
test oil mainly contained linseed oil (Erfurter Ölmühle,
Germany) mixed with sunflower oil (K-Classic, Germany)
to receive a ratio of linoleic acid (LA)/ALA of 0.7/1.0. The
composition of the test oil was characterized by a high
content of total PUFA (>50%) consisting of 31% ALA and
22% LA (Table 2). The control oil was a highly refined
olive oil (Gustav Heess GmbH, Germany) with a small
amount of PUFA (6%), mainly LA, and a high amount of
the monounsaturated FA (MUFA) oleic acid (OA) at 78%
(Table 2). According to gender specific energy recommen-
dations, female subjects consumed 15.5 g/d and male sub-
jects 18.5 g/d of the test oil or control oil during the
intervention period. The oil was mainly taken pure or in
addition to other food. Subjects were instructed to store
the oils in the cold (4-7°C) and dark. Participants and
scientific staff involved in the study were blinded. Oil cups
of test and control oil were standardized and labeled using
a numeric code.Table 2 FA composition of supplemented oils and daily consu
Run-in oil
Total subjects (n = 38)
Oil Intake1 Oi
Major FA [% FAME] [g/d] [%
Daily dose 17.0
Σ SFA 36.6 5.60 8.9
C18:1n-9 (OA) 45.1 6.90 36
C18:2n-6 (LA) 16.8 2.60 21
C18:3n-3 (ALA) 0.18 0.03 31
Σn-6/Σn-3 94.0/1.0 0.7
FA of supplemented oils are presented as means [% FAME].
1Daily intake is given as mean of men and women; men received 18.5 g/d and wom
2200 kcal for women to achieve comparable energy% of the supplemented FA forCheek cell sampling
Cheek cell sampling was performed in the morning after
the fasting blood samples were taken. The subjects were
instructed not to eat or drink, but to brush their teeth prior
to cheek cell sampling. Before cell collection, subjects had
to clean their mouth by rinsing with 20 ml distilled water.
The cheek cell removal was performed with sterile cell
brushes (Cytobrush® Plus GT, Medscand® Medical,
Germany) by scraping and rotating one brush up and down
(20 times) on the inside of each cheek. Both cell brushes
were placed in 50 ml tubes containing 10 ml distilled water
and covered with a screw cap. Subsequently, subjects rinsed
their mouth again with 20 ml distilled water which was
then added to the 50 ml tube. The tubes were stored on
ice. Cheek cells were suspended in the water in the tube
and each brush was rinsed with 2.5 ml distilled water to re-
move the majority of the cells. After centrifugation (10 min,
3750 × g) the supernatant was carefully discarded. The cell
pellets were washed once again with distilled water, and
then suspended in a total volume of 4 ml distilled water for
transfer into a 4 ml tube. The samples were stored at −80°C
until the end of the study (approx. 4 months).
For analyzing the distribution of lipid fractions of total
cheek cell lipids and phospholipids (PL), separatemed dose during the study
Linseed oil mix Olive oil
Test group (n = 23) Control group (n = 15)
l Intake1 Oil Intake1
FAME] [g/d] [% FAME] [g/d]
17.0 17.0
9 1.38 13.9 2.13
.3 5.55 77.5 11.9
.6 3.30 5.52 0.85
.1 4.85 0.52 0.08
/1.0 11.0/1.0
en 15.5 g/d total daily dose; based on average 2800 kcal for men and
both sexes.
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(n = 10). Fractionation was done by use of high perfor-
mance thin-layer chromatography and scanned by means
of densitometry at 400 nm [16].
Fatty acid analysis of cheek cells, plasma, RBC, PBMC
The blood sampling, the preparation of plasma, RBC and
PBMC and the GC method were performed according to
Kuhnt et al. [15,17]. Lipid extraction of cheek cell and
blood samples was conducted with chloroform/methanol/
water (2:1:1; v/v/v) according to Folch et al. [18]. The
transesterification was performed with boron triflouride.
The purification of fatty acid methyl esters (FAME) by
thin-layer chromatography, e. g. exclusion of the choles-
terol fraction was only conducted for blood fractions. In
cases of the cheek cell samples purification was omitted
caused by small sample amounts. FAME were analyzed
by gas chromatography with flame ionization detector
(GC-17 V3, Shimadzu, Japan; column: DB-225MS, 60 m ×
0.25 mm i.d. with 0.25 μm film thickness, Agilent Tech-
nologies, U.S.). Oven temperature was initially maintained
at 70°C for 2 min, increased by 10°C/min to 180°C, further
increased by 2°C/min to 220°C and held for 5 min. During
the final step it was increased by 2°C/min to 230°C and
held for 27 min.
The injection volume for blood fraction extracts was
1 μl and for cheek cell lipid extracts was 2 μl with a split
mode of 1:20, respectively. In all analyzed materials the
same 47 fatty acids were integrated (C10 - C24). Individ-
ual FAME were expressed as a percentage of total identi-
fied FAME peak areas [% of total FAME; % FAME]. A
series of external standards were used for the qualitative
analysis of FAME (No.463, 674 (Nu-Check Prep, USA),
BR2, BR4, ME93 (Larodan, Sweden), Supelco®37 Compo-
nent FAME Mix (Supelco, USA) and PUFA No.3
(Matreya LLC, USA). The peak integration of the chro-
matograms was performed with LabSolutions software
for gas-chromatography (GCsolution, Shimadzu, Japan).
Statistical analyses
All statistical analyses were performed using IBM SPSS
software, version 20.0 (IBM, USA) with P ≤ 0.05 indicat-
ing significance. FAME levels are given as mean and
standard deviation (SD). Data were tested for normal
distribution and variance homogeneity. The t-test was
used for comparison of the two treatment groups. When
data were not normally distributed according Kolmogorov
Smirnov test the comparison was based on the Mann
Whitney U Test.
Effects on FA composition within each treatment on
FA composition were analyzed with general linear model
repeated-measures analysis. To test the differences at
the end of the study (day 56) between the treatments
(treatment as fixed factor) baseline values and age wereused as covariate (univariate ANCOVA) using bonfer-
roni adjustment. FA portions of cheek cells were com-
pared with FA portions of different blood fractions using
one-way ANOVA with Dunnett-T3 test for multiple
comparison. A correlation analysis was conducted be-




The baseline body weight, body mass index (BMI), waist
circumference and blood pressure did not differ between
the test group and control group (Table 1). The age dis-
tribution between the study groups differed, but had
similar median age of 25 years. All 38 subjects of this
cheek cell subgroup finished the entire study successfully
and consumed the supplemented oils (by self-report and
counted oil packages).
Cheek cell FA composition
The analysis of the lipid fractions of cheek cell lipids was
conducted independent of cheek cell samples of the
study. Therefore, the presented data refer to pooled
cheek cell samples of various donors. Cheek cell lipids
mainly contained PL (57%), whilst triglycerides, choles-
terol and non-esterified FA amounted to 20%, 19% and
4%, respectively. Moreover, the total PL fraction com-
prised of similar proportions of phosphatidylcholine,
sphingomyelin and phosphatidylethanolamine (35%,
31%, 30% of total PL), whereas only 3% phos-
phatidylinositol was present. Lastly, lysophosphatidyl-
choline and phosphatidylserine were below the detection
limit.
Regarding cheek cell samples of the intervention study,
the main FA portions at baseline were the saturated fatty
acids (SFA) palmitic acid (C16:0) and stearic acid
(C18:0), the n-9 MUFA OA and the n-6 PUFA LA.
Compared to these, n-3 PUFA portions only contribute
less than 2% to the FA composition of cheek cells
(Tables 3 and 4).
The linseed oil supplementation in the test group (n = 23)
resulted in a significant increase of ALA portion in cheek
cells from 0.27% FAME at baseline, to 0.39% FAME after
7 days and to 0.50% FAME after 56 days of intervention
(P≤ 0.001; Table 3). In addition, long-chain n-3 PUFA,
such as eicosatetraenoic acid (ETA), eicosapentaenoic acid
(EPA) and docosapentaenoic acid (DPA), endogenously
derived from ALA as precursor and increased significantly
in cheek cells after 56 days of linseed oil intervention.
However, docosahexaenoic acid (DHA) portion remained
unchanged. The n-3 PUFA ALA and ETA already showed
significant increase after 7 days, while the conversion
products EPA and DPA increased only after 56 days of
supplementation. Due to the increase of n-3 PUFA in
Table 3 Cheek cell FA composition during supplementation with linseed oil mix and olive oil
FA [% FAME]
Test group - linseed oil mix (LO) (n = 23) Control group - olive oil (OO) (n = 15) LO x OO
Day 0 Day 7 Day 56 Day 0 Day 7 Day 56 Day 56
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD P1
SFA
C16:0 17.1 ± 2.20a 16.9 ± 2.14ab 15.9 ± 1.75b 17.0 ± 1.55 16.9 ± 1.89 16.6 ± 2.18 0.590
C18:0 16.7 ± 3.82 15.9 ± 3.08 15.8 ± 2.78 16.3 ± 2.71 15.3 ± 1.60 16.1 ± 2.25 0.672
n-9 MUFA
C18:1n-9 (OA) 27.0 ± 3.76b 26.6 ± 3.00b 28.0 ± 2.93a 26.4 ± 2.47b 27.8 ± 1.75a 27.9 ± 2.59a 0.222
Total n-9 27.4 ± 3.78b 27.0 ± 3.01b 28.4 ± 2.92a 26.8 ± 2.49b 28.3 ± 1.76a 28.4 ± 2.55a 0.206
n-6 PUFA
C18:2n-6 (LA) 16.6 ± 2.01b 18.2 ± 4.79ab 17.4 ± 1.93a 17.9 ± 2.04 17.8 ± 1.90 16.6 ± 1.61 0.070
C18:3n-6 0.10 ± 0.03a 0.09 ± 0.03b 0.10 ± 0.04ab 0.09 ± 0.03 0.10 ± 0.02 0.11 ± 0.03 0.306
C20:3n-6 1.20 ± 0.28 1.13 ± 0.33 1.18 ± 0.25 1.09 ± 0.13b 1.09 ± 0.22b 1.18 ± 0.23a 0.108
C20:4n-6 (AA) 3.15 ± 0.74 3.18 ± 0.89 3.30 ± 0.73 3.58 ± 0.74 3.61 ± 0.68 3.71 ± 0.69 0.215
C22:5n-6 0.06 ± 0.03 0.06 ± 0.03 0.07 ± 0.05 0.07 ± 0.01b 0.07 ± 0.02b 0.08 ± 0.02a 0.259
Total n-6 21.6 ± 2.51b 23.2 ± 4.70ab 22.6 ± 2.33a 23.4 ± 2.18 23.3 ± 1.94 22.3 ± 1.89 0.350
n-3 PUFA
C18:3n-3 (ALA) 0.27 ± 0.10c 0.39 ± 0.09b 0.50 ± 0.18a 0.31 ± 0.18 0.25 ± 0.06 0.26 ± 0.11 0.001
C20:4n-3 (ETA) 0.06 ± 0.03c 0.08 ± 0.05b 0.11 ± 0.03a 0.05 ± 0.01 0.05 ± 0.02 0.05 ± 0.02 0.001
C20:5n-3 (EPA) 0.21 ± 0.08b 0.23 ± 0.09b 0.33 ± 0.11a 0.22 ± 0.08 0.24 ± 0.11 0.22 ± 0.07 0.001
C22:5n-3 (DPA) 0.20 ± 0.07b 0.20 ± 0.08b 0.30 ± 0.10a 0.27 ± 0.09 0.29 ± 0.10 0.26 ± 0.09 0.006
C22:6n-3 (DHA) 0.77 ± 0.24 0.83 ± 0.34 0.76 ± 0.28 0.82 ± 0.28 0.82 ± 0.29 0.76 ± 0.22 0.796
Total n-3 1.62 ± 0.37c 1.87 ± 0.50b 2.16 ± 0.58a 1.77 ± 0.51 1.75 ± 0.45 1.70 ± 0.42 0.001
Sum
Σ SFA 40.8 ± 6.23a 39.6 ± 6.01ab 38.3 ± 4.69b 39.8 ± 3.31 38.8 ± 2.78 39.5 ± 4.48 0.616
Σ MUFA 35.9 ± 5.04 35.3 ± 3.92 36.8 ± 4.19 34.9 ± 2.65b 36.0 ± 2.31a 36.4 ± 3.23a 0.294
Σ PUFA 23.3 ± 2.72b 25.2 ± 4.65b 24.9 ± 2.66a 25.3 ± 2.46 25.2 ± 1.93 24.1 ± 1.85 0.099
Ratio
n-6/n-3 13.9 ± 3.22a 13.5 ± 5.63a 11.0 ± 2.44b 13.9 ± 2.75 14.1 ± 3.63 13.9 ± 3.75 0.001
AA/EPA 15.9 ± 4.33a 14.8 ± 4.19a 10.6 ± 2.49b 17.5 ± 5.50 17.1 ± 5.64 18.2 ± 7.00 0.001
Values are presented as mean ± SD.
All FA were statistically analyzed with GLM repeated-measured analysis; abcDifferent letters indicate significant differences between FA proportions within the
treatment groups (P ≤ 0.05); 1Differences between the test group and control group at day 56 (end of intervention) were analyzed with GLM univariate ANCOVA
(age and baseline value as covariate, pairwise comparison with bonferroni adjustment).
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n-6/n-3 PUFA as well as arachidonic acid (AA)/EPA de-
creased significantly from 13.9 to 11.0 and from 15.9 to
10.6, respectively. Additionally, LA and total n-6 PUFA
portions increased during linseed oil intervention (P≤
0.009). The olive oil supplementation in the control group
(n = 15) resulted in a slight increase of OA in cheek cells
from 26.4% FAME at baseline to 27.9% FAME after
56 days (P≤ 0.05). No changes occurred in any n-3 PUFA
in the control group (Table 3).
Given the fact that the FA composition of cheek cells
in both groups did not differ at baseline; at the end of
the study, a significantly higher portion of n-3 PUFA,
such as ALA, ETA, EPA, DPA, and total n-3 PUFA, wasdetected in the test group as compared to the controls.
The ratios of n-6/n-3 PUFA and AA/EPA were signifi-
cantly lower in the test group compared to controls after
intervention (Table 3).
In addition, a subgroup of seven subjects allocated to
the test group provided cheek cells after one week of
wash-out at day 63. Interestingly, a significant decrease
of ALA (day 0: 0.24, day 56: 0.48, day 63: 0.28% FAME)
and ETA portions (day 0: 0.05, day 56: 0.12, day 63:
0.07% FAME) and a slight but not significant decrease of
EPA (day 0: 0.21, day 56: 0.38, day 63: 0.35% FAME) and
DPA portions (day 0: 0.20, day 56: 0.32, day 63: 0.29%
FAME) were already detectable one week post-
supplementation.
Table 4 Comparison of FA profile in cheek cells, plasma,
RBC and PBMC (baseline; n = 38)
FA [% FAME] Cheek cells Plasma RBC PBMC
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
SFA
C16:0 17.1 ± 1.95a 23.9 ± 1.46b 28.2 ± 1.46c 19.3 ± 1.32d
C18:0 16.5 ± 3.39a 6.57 ± 0.73b 10.7 ± 1.14c 20.5 ± 1.16d
n-9 MUFA
C18:1n-9 (OA) 26.7 ± 3.29 a 20.9 ± 1.99 b 17.2 ± 1.06c 16.3 ± 0.85c
Total n-9 27.2 ± 3.30a 21.2 ± 2.00b 17.6 ± 1.09c 17.2 ± 0.86c
n-6 PUFA
C18:2n-6 (LA) 17.1 ± 2.10a 30.8 ± 3.15b 13.6 ± 1.14c 5.76 ± 1.51d
C18:3n-6 0.10 ± 0.03a 0.29 ± 0.09b 0.05 ± 0.01c 0.05 ± 0.01c
C20:3n-6 1.16 ± 0.24a 1.50 ± 0.31b 1.56 ± 0.31b 1.40 ± 0.30b
C20:4n-6 (AA) 3.32 ± 0.76a 6.39 ± 1.05b 13.9 ± 0.93c 24.8 ± 1.42d
C22:5n-6 0.06 ± 0.02a 0.12 ± 0.04b 0.38 ± 0.10c 0.24 ± 0.07d
Total n-6 22.3 ± 2.52a 39.4 ± 3.18b 32.7 ± 1.42c 34.8 ± 1.62d
n-3 PUFA
C18:3n-3 (ALA) 0.29 ± 0.13a 0.40 ± 0.07b 0.14 ± 0.03c 0.06 ± 0.02d
C20:4n-3 (ETA) 0.05 ± 0.02a 0.07 ± 0.03b 0.06 ± 0.02b 0.04 ± 0.01b
C20:5n-3 (EPA) 0.22 ± 0.08a 0.51 ± 0.16b 0.75 ± 0.28c 0.31 ± 0.08d
C22:5n-3 (DPA) 0.22 ± 0.08a 0.39 ± 0.11b 2.09 ± 0.33c 1.56 ± 0.28d
C22:6n-3 (DHA) 0.79 ± 0.25a 1.44 ± 0.39b 3.91 ± 0.90c 1.66 ± 0.32d
Total n-3 1.68 ± 0.43a 3.06 ± 0.55b 7.07 ± 1.21c 3.69 ± 0.45d
Sum
Σ SFA 40.4 ± 5.24ac 32.6 ± 1.25b 40.4 ± 0.89a 41.9 ± 1.27c
Σ MUFA 35.5 ± 4.24a 25.0 ± 2.53b 19.8 ± 1.19c 19.7 ± 0.94c
Σ PUFA 24.1 ± 2.77a 42.4 ± 3.20b 39.8 ± 1.11c 38.5 ± 1.42d
Ratio
n-6/n-3 13.9 ± 3.01a 13.3 ± 2.79a 4.77 ± 0.94b 9.58 ± 1.45c
AA/EPA 16.6 ± 4.81a 13.7 ± 4.67a 20.5 ± 6.45b 85.4 ± 21.5c
Values are presented as Mean ± SD.
abcdIndicates significant differences between FA of the different matrices
(one-way ANOVA; post-hoc Dunnett-T3 test for multiple comparison; P ≤ 0.05).
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plasma, RBC and PBMC
Comparing the FA composition of cheek cells with
plasma, RBC and PBMC, it should be considered that
each fraction has its specific FA profile (Table 4). There-
fore, partially strong variations occurred regarding the
FA composition between the four fractions. Almost all
analyzed FA of plasma, RBC, PBMC and cheek cells at
baseline were significantly different (P ≤ 0.05) to each
other (Table 4).
In general, cheek cells contained the lowest portion of
total PUFA and the highest portion of OA and therefore
of MUFA. Total n-3 PUFA portion of cheek cells
amounted to only ~1.7% FAME. In contrast, total n-3PUFA portion of RBC amounted for ~7.1% FAME and
therefore was almost 4.5-fold higher than in cheek cells
(Table 4). Especially DPA and DHA differed between the
fractions and were therefore 2 - 8-fold higher in plasma
and even 5 - 10-fold higher in RBC compared to cheek
cells (Table 4).
After the intervention with linseed oil or olive oil,
changes in lipids of the blood material (data not shown)
were comparable to changes of cheek cell lipids. Upon
closer examination, the n-3 PUFA ALA, ETA, EPA and
DPA significantly increased in lipids of plasma, RBC and
PBMC after linseed oil intervention, whereas n-3 PUFA
remained unchanged in the olive oil group.
Correlation between FA of cheek cells with FA of plasma,
RBC and PBMC
No significant correlations were found between SFA of
cheek cells and SFA of the three blood fractions at either
baseline or during both treatments. At baseline, OA and
total n-9 MUFA correlated between cheek cells and
plasma (r 0.34 and 0.33, respectively), but not between
cheek cells and RBC or PBMC (Table 5). Individual n-6
PUFA such as gamma-linolenic acid (C18:3n-6),
dihomo-gamma-linolenic acid (C20:3n-6), AA, and
DPAn-6 showed significant correlations between cheek
cells and plasma (r 0.33, 0.41, 0.54 and 0.52, respectively)
or RBC (r 0.44, 0.47, 0.54 and 0.58, respectively)
(Table 5). However, no significant correlations between
cheek cells and the blood fractions were found in LA
and total n-6 PUFA at baseline. Interestingly, total n-6
PUFA and also total PUFA showed negative correlations
(not significant) between cheek cells and the three blood
fractions. In contrast, all analyzed n-3 PUFA of cheek
cells correlated significantly with the respective n-3
PUFA in plasma, RBC and PBMC (except for ALA) (r
0.47 - 0.82; Table 5). Plasma lipids correlated signifi-
cantly with RBC and PBMC lipids in regard of n-3
PUFA. In addition, single n-6 PUFA and single SFA cor-
related significantly between plasma and RBC lipids,
while less correlation were found between PBMC and
plasma lipids (Table 5).
For a higher power and better comparability of the
correlation coefficients between baseline (n = 38) and the
intervention period, the data at day 7 and day 56 of each
treatment group were combined (test group n = 46, con-
trol group n = 30; Table 5). During the intervention with
linseed oil and olive oil correlation coefficients of single
FA of cheek cells to the respective FA in all blood frac-
tions were similar to the baseline correlation coefficients.
In general, the correlation of total n-3 PUFA and single
n-3 PUFA between cheek cells and all blood fractions
were always positive and significant which was inde-
pendent of the treatment, except for ALA. The ALA in-
take by linseed oil resulted in significant correlation of
Table 5 Correlation between cheek cell FA with FA of plasma, RBC and PBMC
Baseline Intervention‡
Total subjects Test group – linseed oil mix Control group – olive oil
(n = 38) (n = 46) (n = 30)
Cheek cell correlation Plasma correlation Cheek cell correlation Cheek cell correlation
Plasma RBC PBMC RBC PBMC Plasma RBC PBMC Plasma RBC PBMC
r1 r1 r1 r1 r1 r1 r1 r1 r1 r1 r1
SFA
C16:0 −0.08 −0.1 0.09 0.80** 0.31 −0.01 −0.2 −0.1 0.34 −0.17 0.34
C18:0 0.04 −0.16 −0.07 0.60** 0.15 0.09 0.04 −0.14 0.05 0.22 −0.03
n-9 MUFA
C18:1n-9 (OA) 0.34* 0.06 0.19 0.16 0.26 0.11 −0.05 −0.01 0.43* 0.25 0.2
Total n-9 0.33* 0.08 0.16 0.17 0.23 0.11 −0.05 0 0.43* 0.29 0.25
n-6 PUFA
C18:2n-6 (LA) −0.59 0.21 0.31 0.58** −0.13 −0.01 0.11 0.12 0.34 0.65** 0.73**
C18:3n-6 0.33* 0.44** 0.1 0.72** 0.07 0.16 0.35* 0.14 0 0.24 0.40*
C20:3n-6 0.41** 0.47** 0.44** 0.86** 0.70** 0.44** 0.50** 0.39** 0.56** 0.65** 0.64**
C20:4n-6 (AA) 0.54** 0.54** −0.21 0.54** 0.09 0.41** 0.41** −0.15 0.38* 0.50** 0.12
C22:5n-6 0.52** 0.58** 0.60** 0.79** 0.76** 0.22 0.27 0.2 0.52** 0.68** 0.54**
Total n-6 −0.22 −0.07 −0.11 0.22 −0.04 −0.19 −0.25 −0.05 0.23 0.44* 0.22
n-3 PUFA
C18:3n-3 (ALA) 0.17 0.06 0.07 0.70** 0.43** 0.33* 0.43** 0.22 0.31 0.1 −0.17
C20:4n-3 (ETA) 0.54** 0.59** 0.48** 0.92** 0.80** 0.36** 0.58** 0.48** 0.60** 0.59** 0.70**
C20:5n-3 (EPA) 0.81** 0.82** 0.62** 0.84** 0.72** 0.69** 0.72** 0.54** 0.84** 0.83** 0.83**
C22:5n-3 (DPA) 0.73** 0.67** 0.47** 0.83** 0.74** 0.55** 0.41** 0.49** 0.48** 0.51** 0.37*
C22:6n-3 (DHA) 0.68** 0.64** 0.59** 0.88** 0.80** 0.50** 0.59** 0.56** 0.61** 0.59** 0.64**
Total n-3 0.58** 0.61** 0.50** 0.85** 0.66** 0.45** 0.57** 0.55** 0.58** 0.64** 0.60**
Sum
Σ SFA −0.24 −0.25 0.05 0.52 −0.25 −0.05 −0.24 0.01 0.27 0.01 0.09
Σ MUFA 0.27 0.06 −0.06 0.12 0.14 0.00 0.05 −0.09 0.32 0.24 0.06
Σ PUFA −0.21 −0.07 −0.2 0.23 −0.10 −0.16 −0.12 −0.01 0.17 0.09 0.11
‡Results of day 7 and day 56 of each intervention combined.
1r Pearson's correlation coefficient; * P ≤ 0.05, ** P ≤ 0.01.
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(r 0.43) (Table 5), whereas without intervention and in
the control group no correlations were found.
Discussion
Since the 1980s, analyses of FA in cheek cells were
undertaken as a non-invasive alternative to identify the
dietary intake of FA [12,19]. However, only few studies
evaluated cheek cell lipids as a marker for the FA status,
especially for n-3 PUFA supply [10,11,20–24]. This study
is the first which examined the changes in n-3 PUFA of
cheek cells after intervention with ALA-rich linseed oil
compared to a n-3 PUFA-free control oil. In addition, al-
terations in the FA composition of cheek cells were
compared to three blood fractions.Cheek cell sampling is a non-invasive method that can
be easily performed in a non-clinical environment, and
was tolerated well by all participants of the present
study. Cheek cells were collected by rotary scraping with
one brush at the inside of each cheek, followed by a
mouth-rinse to collect remaining cells. This sampling
procedure had been evaluated as the most effective adult
sampling procedure by Klingler et al. [25] as well as by
preliminary tests of our group. However, it has to be
noted that the cell yield varied substantially between
subjects. Previous data revealed a mean cell count of 3.5 ±
1.4 × 106 cheek cells/per sampling [26]. Therefore, strict
guidelines regarding the use of cheek cell lipids as markers
for the FA status should be followed to avoid variation in-
cluding sampling- and analytical procedures.
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of cell membranes [21]. As lipids and especially PUFA
are incorporated into cheek cell membranes, there is a
focus on PL [20,21] and glycerophospholipids [11,25] in
FA analysis. Advantageously, PL analysis of cheek cell
FA is not much affected by food remains [21]. Our re-
sults confirmed PL as the major lipid class (57%) of
cheek cells. However, regarding a higher lipid yield the
separation of lipid classes was omitted in the present
study and total lipids of cheek cells were used to analyze
the FA composition as reported previously [19,23,24]. In
order to identify possible food-remains in total lipids of
cheek cells, a high amount of lauric acid (C12:0) is consid-
ered as marker for food contamination. Between 4-14% of
lauric acid can be found in total FA of various diets,
whereas cheek cells contain only <0.2% of this FA [20].
The mean portion of lauric acid in the present samples
was 0.22% FAME (data not shown). Therefore, contamin-
ation via food remains could be excluded in our samples,
as far as possible.
In the present study, the additional dietary intake of
~5 g/d ALA increased ALA portion of cheek cell lipids
significantly (Table 3). Lapillone et al., in their study on
piglets [27] found similar results of cheek cell ALA after
a linseed oil diet for two weeks. In human studies, the
FA composition of cheek cells was previously only ana-
lyzed after the supplementation with DHA [11] or EPA +
DHA [23] in adults, and n-3 PUFA-enriched formula in
infants [10,20]. The present study demonstrated that
cheek cells also represent endogenously synthesized FA.
Besides the increase of the supplemented ALA, the long-
chain n-3 PUFA metabolites such as ETA, EPA, and
DPA also significantly increased in the cheek cell lipids
after eight weeks of linseed oil intervention. Based on
this study’s dietary n-3 PUFA restriction (no fish, fish oil,
other n-3 PUFA-containing oils) these long-chain n-3
PUFA derived from the endogenous conversion of ALA.
No changes occurred in DHA, which confirmed the
very low conversion rate from ALA to DHA reported
at <0.05% [28].
Cheek cells are known as a tissue with a fast regener-
ation time of approximately five days [13]. Therefore
cheek cell FA are thought to be a biomarker detecting
short-term changes in the diet, as it is known from
plasma [6]. This assumption was confirmed by the
present results. Successfully absorbed ALA was incorpo-
rated in cheek cell membranes and was detectable after
already 7 days of a linseed oil intervention (Table 3).
Moreover, after only one week of linseed oil free wash-
out period (n = 7), ALA almost returned to its baseline
values (day 0: 0.24; day 56: 0.48; wash-out day 63: 0.28%
FAME).
Similarities were present when comparing measured
cheek cell FA compositions at baseline with otherstudies, demonstrating the consistency of using cheek
cells as tissue for FA analyses (Table 6). SFA, OA, and
LA were confirmed as major FA while n-3 PUFA
amounted for the smallest portion in previous studies,
despite different analyzed lipid classes [11, 20; Staps and
Kuhnt, unpublished] (Table 6). Notably, the cheek cell
FA composition of the present study corresponded re-
markably well to the study of Klingler et al. [11], espe-
cially regarding n-6 PUFA and n-3 PUFA.
In addition to cheek cell FA, the present study ana-
lyzed the FA of three blood fractions such as plasma,
RBC and PBMC. Comparing the FA profile of these
blood fractions with the cheek cell FA profile, strong
baseline variations were found (Table 4). After interven-
tion with either linseed oil or olive oil, similar changes
occurred in blood matrices (data not shown) as well as
in cheek cell FA (Table 3). Interestingly, the increase of
the precursor ALA in the blood fractions (~320%) was
higher compared to the increase of ALA in cheek cells
after linseed oil intervention (87%), while the increase of
the metabolite EPA was similar (47% vs. 56%). Thus,
cheek cells lipids reflect dietary FA, but also endogenous
metabolism. The supplementation of linseed oil led to
an enrichment of n-3 PUFA in all four analyzed mate-
rials and thus decreased the ratios of n-6/n-3 PUFA and
AA/EPA. Therefore, linseed oil consumption could con-
tribute to beneficial health effects such as a reduction of
the CVD risk by improving the n-3 PUFA status in the
body [1]. A general use of linseed oil as a replacement
for the commonly used high n-6 PUFA plant-oils of the
Western diet can be recommended to improve the n-6/
n-3 PUFA ratio in the diet.
In general, the standard analysis of the FA status and
the n-3 PUFA supply in humans is mostly conducted by
analyzing the FA of plasma, RBC, platelets or adipose
tissue as they strongly correlate with the FA content of
the diet [8]. Until now, only little was known about the
correlation of dietary FA intake and cheek cell FA com-
position. However, in some previous studies cheek cell
FA composition was used as marker for the FA supply
and correlations with plasma- and RBC FA were de-
tected [10,11,20,21]. Cheek cells were also reported to
reflect the nutritional intake of FA [10]. Thus, high cor-
relations were found between dietary AA and cheek cell
AA (r 0.51) as well as between dietary DHA and cheek
cell DHA (r 0.65) [20]. The present study did not
analyze the correlation between diet and cheek cell FA,
but showed strong correlations of cheek cell FA with the
respective FA of plasma and RBC, which are both
known markers of FA intake. This emphasizes cheek cell
FA as a biomarker for the FA supply of the diet. As this
was the first study to analyze the correlation between
cheek cell FA and PBMC FA to this extent, it can be
noted that less correlations exist compared to the
Table 6 Comparison of FA composition and cheek cell correlation of the present study with relevant literature
Cheek cell FA composition Cheek cell FA correlation







Present study Klingler et al.
(2013) [11]
Present study










Subjects Infants Adults Adults Adults Adults Adults
(n = 8) (n = 4) (n = 13) (n = 38) (n = 13) (n = 38)
Lipid class Phospholipids Total lipids Glycerophospholipids Total lipids Glycerophospholipids Total lipids
% FAME % FAME mol% % FAME r1 Plasma r1 RBC r1 Plasma r1 RBC
SFA
C16:0 14.5 15.6 16.6 17.1 0.64* 0.32 −0.08 −0.10
C18:0 12.3 11.4 15.3 16.5 0.70** 0.33 0.04 −0.16
n-9 MUFA
C18:1n-9 (OA) 25.8 28.9 30.1 26.7 0.40 0.10 0.34* 0.06
n-6 PUFA
C18:2n-6 (LA) 16.5 18.4 17.3 17.1 −0.04 −0.05 −0.59 0.21
C20:4n-6 (AA) 2.00 4.37 3.20 3.32 0.65** 0.17 0.54*** 0.54***
C22:5n-6 1.00 0.12 0.07 0.06 0.78*** 0.70** 0.52*** 0.58***
n-3 PUFA
C18:3n-3 (ALA) 0.40 0.23 0.24 0.29 0.11 0.13 0.17 0.06
C20:5n-3 (EPA) 0.10 0.55 0.21 0.22 0.66 0.79** 0.81*** 0.82***
C22:5n-3 (DPA) 0.20 0.43 0.23 0.22 0.85 0.39 0.73*** 0.67***
C22:6n-3 (DHA) 0.40 1.07 0.69 0.79 0.76*** 0.88*** 0.68*** 0.64***
1r Pearson's correlation coefficient; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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RBC. However, in cases of n-3 PUFA the correlations be-
tween cheek cells and PBMC are still highly significant
(r 0.47–0.62; Table 5).
Upon closer examination high correlations of cheek
cell EPA and DHA to the respective FA of plasma
and RBC were previously described [11,20,25,27]. This
could be confirmed by the present results regarding
the correlations of n-3 PUFA ETA, EPA, DPA, DHA,
and total n-3 PUFA between cheek cells and plasma,
RBC as well as PBMC (Table 5). Otherwise, cheek
cell FA seemed to be unsuitable as an adequate bio-
marker for SFA in body lipids shown by the present
results and Skeaff et al. [29]. Paradoxically, total n-6
PUFA of cheek cells correlated negatively to the total
n-6 PUFA of the analyzed blood lipids despite major
part of individual n-6 PUFA correlated positively
(Table 5). Laitinen et al. found similar observations
with regard to correlations of n-6 PUFA between
cheek cell- and serum FA [22]. Most likely this could
be due to the different amounts and opposed portions
of LA and AA seen in the various blood fractions
(Table 4). However, best correlations were found be-
tween plasma and RBC.When comparing the correlation analysis by Klingler
et al. [11] with the present results at baseline, similar re-
sults were obtained indicating again the consistency of
this method (Table 6). No correlations were found for
the essential FA LA and ALA between cheek cells and
plasma or RBC in both studies. Despite a lower subject
number in the study of Klingler et al. [11], correlations
between cheek cells and plasma or RBC in AA, DPAn-
6, EPA, and DHA were reported. Especially significant
correlation of EPA and DHA of cheek cells with plasma
and RBC (r 0.61-0.94) were also observed in the other
studies [20,25,27].
Based on the present knowledge, cheek cell FA mainly
represented n-3 PUFA and n-6 PUFA status related to
plasma and RBC. However, this did not apply for SFA.
Especially when blood samples are not available, cheek
cell lipids could represent an alternative.
Conclusions
The present results indicate cheek cell FA as a non-
invasive biomarker for both dietary n-3 PUFA supply
and endogenously derived n-3 PUFA metabolites. The
present results indicated that ALA intake by linseed oil
increased EPA and lowered the n-6/n-3 PUFA ratio in
Grindel et al. Lipids in Health and Disease 2013, 12:173 Page 10 of 10
http://www.lipidworld.com/content/12/1/173cheek cell lipids. Cheek cell FA can used as alternative
to FA of plasma and RBC to determine dietary FA in-
take, with special regard to n-3 PUFA. In general, the FA
profile of cheek cells mainly reflected short-term changes.
Furthermore, the non-invasive sampling procedure is an
advantage to study participants and can be performed in-
dependently of clinical personnel. Therefore, the assess-
ment of cheek cell FA can be considered for human
intervention studies and large-scale epidemiological stud-
ies where the n-3 PUFA supply and its metabolism are of
interest.
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